Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RTI-LNG1
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Khosla Ventures
Deal Size : $10.6 million
Deal Type : Financing
Details : The funding will be used to advance its programs, including RTI-LNG1, to IND approval in fibrotic disease, such as pulmonary fibrosis and liver cirrhosis, as well as early research targeting the immune system.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 06, 2023
Lead Product(s) : RTI-LNG1
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Khosla Ventures
Deal Size : $10.6 million
Deal Type : Financing